Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses (NCT07631598)
Buprenorphine Implementation at Syringe Services Programs To Reduce Overdoses: A Type 1 Hybrid Effectiveness-Implementation Trial
🩺 Plain-English Summary (8th-Grade Level)
This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms. The study compares two ways of connecting people to treatment: Referral to a community treatment provider (usual care before the new program begins). Onsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider. Participants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after the new program begins to see how it affects treatment engagement and health outcomes. The study will also examine how easy or difficult it is for SSPs to start and run the new program, how acceptable it is to staff and participants, and whether it is cost-effective. The overall goal is to find better ways to expand access to life-saving opioid treatment in community-based settings.
Who can join: Review the eligibility criteria below.
Location: Community Health Project Los Angeles (CHPLA) — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
- Standard of Care Referral (OTHER)
- Low Threshold Buprenorphine (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Community Health Project Los Angeles (CHPLA) — Los Angeles, California
- HIPS — Washington D.C., District of Columbia
- CARPBR/Be Safe Syringe Program — Baton Rouge, Louisiana
- Harm Reduction Sisters — Duluth, Minnesota
- Alianza of New Mexico — Roswell, New Mexico
- HIV Alliance — Grants Pass, Oregon
- Challenges, Inc/Prisma Health — Greenville, South Carolina
- Vivent Health — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (203) 606-8136
Email: mghiroli@montefiore.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Opioid Use Disorder
- Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder — Atlantic City, New Jersey
- The Emergency Department Longitudinal Integrated Care — Seattle, Washington
- Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT — La Jolla, California
- Extended-release Buprenorphine as a Novel Low-dose Induction Strategy — Boston, Massachusetts
- Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial — Ann Arbor, Michigan
- Telemedicine XR-B for Individuals in Jail — Cumberland, Maryland
Explore by condition: All Opioid Use Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.